Home › Funds › Sofinnova Investments, Inc. › TRAX
Sofinnova Investments, Inc. position in TRAX
FIRST TRACKS BIOTHERAPEUTICS · Health Care
Sofinnova Investments, Inc. reported holding 383,588 shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$13.6M, representing 0.61% of its reported portfolio and ranking #34 among its reported holdings. Sofinnova Investments, Inc. has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Sofinnova Investments, Inc.'s TRAX position evolved
Sofinnova Investments, Inc. first disclosed a stake in TRAX in Q2 2026 at 565,199 shares (US$11.4M). The position peaked in Q3 2026 at 383,588 shares, worth US$13.6M. Across 2 filings, Sofinnova Investments, Inc. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 383,588 shares valued at US$13.6M — a reduction of -181,611 shares quarter over quarter.. Notable position changes include a 32% trim in Q3 2026 (shares rose 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 565.20K | $11.37M | New |
| Q3 2026 | 383.59K | $13.59M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRAX and 13F data
TRAX (FIRST TRACKS BIOTHERAPEUTICS) is a Health Care company. 181 other funds we track also report a position in TRAX — the largest reported positions include EcoR1 Capital, LLC (US$112.5M), TCG Crossover Management, LLC (US$102.6M), Affinity Asset Advisors, LLC (US$73.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRAX
- EcoR1 Capital, LLC 3.17M sh · $112.50M · Q3 2026
- TCG Crossover Management, LLC 2.90M sh · $102.61M · Q3 2026
- Affinity Asset Advisors, LLC 2.08M sh · $73.72M · Q3 2026
- Sanofi 821.92K sh · $29.13M · Q3 2026
- Trails Edge Capital Partners, LP 814.00K sh · $28.85M · Q3 2026
- STEMPOINT CAPITAL LP 649.92K sh · $23.03M · Q3 2026
- 683 Capital Management, LLC 600.00K sh · $21.26M · Q3 2026
- Vestal Point Capital, LP 1.01M sh · $20.38M · Q2 2026
- Palo Alto Investors LP 603.49K sh · $12.14M · Q2 2026
- Ally Bridge Group (NY) LLC 284.29K sh · $5.72M · Q2 2026
- Opaleye Management Inc. 65.00K sh · $1.31M · Q2 2026
More on Sofinnova Investments, Inc.
FAQ
How long has Sofinnova Investments, Inc. held TRAX?
Sofinnova Investments, Inc. has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Sofinnova Investments, Inc.'s current position in TRAX?
As of Q3 2026, Sofinnova Investments, Inc. holds 383.59K shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS), valued at $13.59M, representing 0.61% of its reported portfolio and ranking #34.
Has Sofinnova Investments, Inc. been buying or selling TRAX?
In the latest 13F filing (Q3 2026), Sofinnova Investments, Inc. reduced its position in TRAX. The position peaked in Q3 2026 at 383.59K shares.
Which other funds hold TRAX?
Other major institutional holders of TRAX include EcoR1 Capital, LLC, TCG Crossover Management, LLC, Affinity Asset Advisors, LLC, among 181 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.